Predict your next investment

Private Equity

See what CB Insights has to offer

Investments

32

About Hengxu Capital

Hengxu Capital is the FoF management platform under SAIC Capital that invests in advanced manufacturing, big healthcare, and others. The company invests in Hillhouse and Boyu mature funds.

Hengxu Capital Headquarter Location

Shanghai, Shanghai,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hengxu Capital News

Ushopal Completes USD100M Financing

Mar 10, 2021

Ushopal , a Shangai, China-based new luxury beauty and new retail group, completed a USD100m financing. The round was led by FountainVest Partners, with participation from Cathay Capital, Zhongyuan Capital, Hengxu Capital and Dazhong Zhongsong Fund. The company intends to use the funds for continued growth in China and Asia Pacific. Founded in 2017 by Lu Guo, CEO, Ushopal focuses on niche, global luxury beauty brands. Its portfolio mainly covers brands exclusively sold at high-end retail outlets such as Harrods from the UK, Le Bon Marché from France, Neiman Marcus from the US, etc. With gross merchandise value (GMV) in 2020 surpassing 200m USD, the company’s portfolio of luxury niche brands inc lude major new luxury beauty players in China, such as Natura Bisse, Juliette Has a Gun, Chantecaille, and more. Ushopal offers omni-branding and growth capabilities for portfolio brands with a fleet of more than 2,500 luxury influencers, an in-house content studio, branding team, an omni-channel growth team, Tmall retail operations, global logistics and Bonnie & Clyde (BC) – a chain of multi-brand brick-and-mortar brand stores and experience centers. FinSMEs

Hengxu Capital Investments

32 Investments

Hengxu Capital has made 32 investments. Their latest investment was in NANOVISION as part of their Series C on November 11, 2021.

CBI Logo

Hengxu Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/11/2021

Series C

NANOVISION

$78.24M

Yes

5

11/5/2021

Series C

Xgene Pharmaceutical

$40M

Yes

6

10/27/2021

Seed

MOYANG BIOTECHNOLOGY

Yes

1

10/25/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/22/2021

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/11/2021

11/5/2021

10/27/2021

10/25/2021

10/22/2021

Round

Series C

Series C

Seed

Series B

Series A - II

Company

NANOVISION

Xgene Pharmaceutical

MOYANG BIOTECHNOLOGY

Subscribe to see more

Subscribe to see more

Amount

$78.24M

$40M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

6

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.